No Data
China's first mesenchymal stem cell therapy drug has been approved for market launch, with Yidu Technology (02158) strongly promoting it.
The launch of this drug has promoted clinical exploration of stem cell therapy in multiple indications, marking an important milestone in the field of stem cell therapy in our country.
YIDU TECH: 2024/2025 Interim Report
Retail Investors Invested in Yidu Tech Inc. (HKG:2158) Copped the Brunt of Last Week's HK$1.1b Market Cap Decline
Yidu Technology (02158) leverages Doubao and Volcano Engine to explore new growth points in Business.
As a leading enterprise in the AI Medical field, Yidu Technology (02158) has long been engaged in deep cooperation with Volcano Engine, Doubao, and other entities within the Byte ecosystem, with both sides joining forces in technology and ecology to drive business innovation breakthroughs.
Hong Kong stocks movement | Yidu Technology (02158) rose nearly 7% in the morning as AI-assisted diagnosis was included in Medical insurance for the first time. The company launched the AI Medical brain YiduCore.
Yidu Technology (02158) rose nearly 7% in the morning, as of the time of writing, it is up 6.06%, priced at 5.95 Hong Kong dollars, with a transaction volume of 0.141 billion Hong Kong dollars.
Hong Kong stocks anomaly | iMedical Technology (02158) rose more than 6%, recent AI medical related policies have been frequent, adjusted EBITDA continues to be profitable.
Yidu Technology (02158) rose over 6%, as of the time of writing, it increased by 6.11%, priced at 5.56 HKD, with a transaction amount of 0.118 billion HKD.
Here's Why We're Not At All Concerned With Yidu Tech's (HKG:2158) Cash Burn Situation
